Search This Blog

Thursday, July 11, 2019

Air Methods, Global Medical Response most at risk with surprise billing ban

  • The biggest air ambulance companies have the most to lose should a balance billing ban working its way through Congress become federal law, a new report by S&P Global says.
  • According to the report, the companies most at financial risk are Colorado-based Air Methods Corp. and Global Medical Response, both of which derive a large portion of their profits from out-of-network charges. S&P Global says both companies would suffer impaired credit ratings if the current version of a bill currently being debated is passed. The two companies have projected combined 2019 revenues of $5.2 billion and “stable” ratings from S&P, although the ratings firm considers Global Medical Response the stronger of the two companies.
  • The report noted that the proposed legislation “has strong tailwinds” given strong public interest in addressing the issue, as well as bipartisan support in Congress.

S&P Global’s report comes after a Senate committee introduced a bill that takes aim at surprise billing and includes air ambulances after early drafts excluded the aircraft from regulation.
Many Americans each year are exposed to balance billing — being charged by providers in excess of what their insurer allows or covers. It can occur during an emergency room visit, or when a patient is unknowingly put under for surgery by an out-of-network anesthesiologist. These bills often amount to tens of thousands of dollars.
But the potential financial burden placed on patients who need emergency medical transport by air can be significant. That has led to the introduction in the Senate of the Lower Health Care Costs Act, which would ban balance billing in many areas of healthcare, including for air ambulance services. S&P Global expects the bill to reach the Senate floor this month.
The legislation would essentially cap out-of-network rates. First, it would bar air ambulances from sending a balance bill to patients and would allow insurers to pay out-of-network air ambulance providers the median in-network amount, which is based on other negotiated contracts in a given area.
S&P said the surprise billing bans would be the most severe on the air transport industry given the frequency of out-of-network rides, coupled with the high usage of unprofitable transports by Medicare and Medicaid patients.
According to a March report by the Government Accountability Office, the median price for a fixed-wing aircraft emergency medical transport in 2017 was $40,600 and $36,400 for helicopter transport — up 60% since 2012. And 69% of air ambulance transports in 2017 were out-of-network.
“The emergency nature of most air ambulance transports, as well as their relative rarity and high prices charged, reduces the incentives of both air ambulance providers and insurers to enter into contracts with agreed-upon payment rates,” the GAO report noted.
GAO also analyzed air ambulance balance billing complaints in two states, Maryland and North Dakota. Only one balance bill in the group was for less than $10,000. Some topped $50,000 and even $60,000.
Another study published last week by Health Affairs concluded that recent charges to Medicare for air ambulance services were 4.1 to 9.5 times higher than what they were in 2016.
The S&P Global report expects “insurance companies will gain negotiating power in setting in-network rates” if a bill is signed into law. However, it expects the bill will likely be tweaked significantly before a final version is voted on by both chambers of Congress.
The balance billing ban being debated in Congress has raised concerns among major air ambulance providers. Both Air Methods and Global Medical Response prominently feature balance billing-related stories on their corporate websites.
While Global Medical Response has mostly restricted its coverage to its “Newsroom” section, Air Methods has taken a more aggressive approach. Its home page features a story about Karen Epsinosa, a Florida resident who suffered a stroke in 2017 and required emergency air transport. The Air Methods article celebrated the fact that Espinosa’s husband worked for six months with one of its employees to convince their insurer to pay the entire air ambulance bill.

Amazon momentum in medical supply chain slows: UBS poll

  • Providers are allocating a smaller percentage of medical supply purchases to Amazon this year compared to 2018, though they’ve increased the percentage of non-medical office supplies buys, perhaps because companies receive higher discounts in office than medical supplies from the e-commerce giant, a survey of hospital purchasing managers by UBS found.
  • This isn’t ruinous news for the retailer’s health supply chain ambitions, however — a majority of the 100 respondents to the the investment bank’s poll expect to increase their percent allocation of medical supply purchases through Amazon in three years.
  • UBS also found a larger percentage of respondents were using a group purchasing organization (81%) compared to last year (75%), while fewer were using a regional purchasing organization. The percentage of hospitals using Premier grew significantly year over year, from 30% to 44%, largely at the expense of GPO competitor HealthTrust.

E-commerce giant Amazon continues to wiggle into multiple healthcare markets, including at-home prescription drug delivery, HIPAA-compliant artificial intelligence and machine learning, selling glucose monitors and blood pressure cuffs direct to the consumer and more. But this survey’s results are a mixed bag in terms of one area Amazon believes it can majorly disrupt: medical supply chains.
U.S. hospitals could save $25.4 billion annually by streamlining their supply chains to eliminate waste and unnecessary cost, according to a Navigant analysis of 2,300 hospitals. That’s roughly $11 million in savings per hospital per year and a tempting opportunity for supply chain players. The market is forecast to reach $2.3 billion by 2022.
Though Amazon already sells some healthcare and IT equipment to hospitals, integrated delivery systems and physician offices (and touts the cost-saving benefits of its multiple supplier marketplace, Amazon Business), initial provider results vary. Amazon Business head Chris Holt told Healthcare Dive last year the platform helped Summit Pacific Medical Center in rural Washington cut labor expenses by 80%, lowering related spend.
However, New York-Presbyterian was unable to achieve better supply chain pricing by using Amazon, alongside concerns about lack of options or less control over purchases and shipping.
According to the UBS survey, the top reservation health systems have about working with Amazon is lack of control, oversight or standardization (30%), followed by worries around product quality (20%) and limitations on the types of products available (10%). Respondents were less concerned about the three than last year, though the order of reservations remained the same — all contributing to why acute care hospitals seem to be using Amazon less for their medical supplies purchases.
Researchers from UBS aren’t sure whether Amazon’s discounts on medical supplies declined, or if competitors’ prices came more in line with the e-commerce giant, driving clients away.
The survey also dove into utilization and satisfaction with group purchasing organizations, when a group of businesses form a single purchasing entity to obtain discounts from vendors. The country’s some-600 GPOs save the healthcare industry an estimated $34.1 billion annually, according to the Healthcare Supply Chain Association.
Though a greater number of respondents were likely to use Charlotte, North Carolina-based Premier, users reported similar amounts of satisfaction across Premier, HealthTrust and Vizient and its subsidiary MedAssets. Premier customers saw larger discounts versus other GPOs, a boon UBS chalked up to Premier’s sourcing ability and its associated savings. Smaller hospitals expect to see the largest discounts versus mid- and large-size hospitals, UBS found, likely because smaller facilities have more to gain from joining with other groups to leverage purchasing power.

Hookipa on go with study of HB-201 in HPV+ cancers

Thinly traded micro cap HOOKIPA Pharma (NASDAQ:HOOK) is up 37% after hours on modestly higher volume in reaction to the FDA’s sign-off on its IND to start a Phase 1/2 clinical trial evaluating HB-201 for the potential treatment of HPV-positive cancers. The study should launch in H2 with preliminary data available in late 2020/early 2021.
The company says HB-201 is a TheraT-based immunotherapy that expresses a non-oncogenic but highly antigenic E6/E7 fusion protein derived from HPV16, adding that it induced strong immune system responses (E6 and E7 antigen-specific CD8+ T cell response) in animal models. It believes that HB-201 has the potential to induce CD8+ T cell levels on par with adoptive cell therapies in an off-the-shelf approach.

Invitae to acquire Jungla for $50M

Invitae (NYSE:NVTA) has agreed to acquire privately held, Andreessen Horowitz-funded Jungla, a developer of a cloud-based platform that combines clinical knowledge with advances in functional genomics, biophysics, cellular engineering, machine learning, and distributed systems to help clinicians and patients understand the results of genetic and genomic tests.
Under the terms of the deal, Invitae will pay $15M in cash and $35M in common stock. It will also pay up to an additional $15M (mostly stock) upon the achievement of certain milestones.
The transaction should close in the next few days.

Amgen & Novartis bail on Alzheimer’s candidate umibecestat

By mutual agreement, Amgen (NASDAQ:AMGN), collaboration partner Novartis (NYSE:NVS) and Banner Alzheimer’s Institute will terminatedevelopment of BACE1 inhibitor CNP520 (umibecestat) for the potential prevention of Alzheimer’s disease due to lack of efficacy.
Preliminary data from two Phase 2/3 studies showed a worsening of some measure of cognitive function in the treatment groups.

Big Biopharma hit as investors wait for Trump’s drug price plan

Major drug makers are under water nearing the close as skittish investors move the sidelines ahead of President Trump’s plan to peg Medicare reimbursement to the lowest ex-U.S. prices from a select group of countries.
ETFs: BIBGRXTHWBMEBISIXJARKGIDNAXLVPJPXBIIHEXPH
Takeda (TAK -0.3%), Bausch Health Companies (BHC -4.4%), Roche (OTCQX:RHHBY -1.9%), AbbVie (ABBV -1%), Allergan (AGN -0.3%), AstraZeneca (AZN -1.8%), Bristol-Myers Squibb (BMY -3.5%), GlaxoSmithKline (GSK -0.6%), Johnson & Johnson (JNJ -1.1%), Eli Lilly (LLY-4.4%), Merck (MRK -4.9%), Novo Nordisk (NVO -3%), Novartis (NVS-1.5%), Pfizer (PFE -2.7%), Teva Pharmaceutical Industries (TEVA -2.5%)

MannKind completes manufacturing buildout

MannKind (NASDAQ:MNKDannounces the completion of construction of a new high-potency manufacturing suite in its Danbury, CT facility.
The expansion will enable the company to produce dry powder formulations of ingredients such as epinephrine on a commercial scale.
Shares are up 5% after hours.